Funding Alzheimer's Tx Dev with ADDF's Karen Harris

Business Of Biotech

We love to hear from our listeners. Send us a message.

We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the sometimes tumultuous Alzheimer's therapeutics space is valuable to any drug developer working in the cognitive medicines arena. In this episode of the Business of Biotech podcast, we follow Karen's journey from institutional investment banking to the incredibly gratifying work she does now, helping to fund the novel biopharma companies that are working in earnest to solve an emotionally burdensome and expensive problem. Karen shares ADDF's strategy and offers plenty of insight into the value proposition that venture philathropy offers the biotech community. Tune in!

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Hoofdstukken

1. Venture Philanthropy and Alzheimer's Drug Development (00:00:00)

2. Investment Strategies in Fighting Alzheimer's (00:08:09)

3. Venture Philanthropy Model in Biotech (00:21:35)

4. Venture Philanthropy in Biotech Sector (00:34:29)

5. Future Alzheimer's Approval and BioTech Builders (00:39:11)